Therapeutic Antibodies – Webinars and Online Events

Charge heterogeneity is often a critical quality attribute, which must be monitored throughout the development of a therapeutic protein and during quality control release.

This exclusive Technology Networks webinar focuses on the most recent and innovative strategies for therapeutic antibody development and production. Your speaker, Professor Brockwell, will describe the development and use of a new assay to investigate important proteins in disease screening and the biopharmaceutical industry.

This webinar discusses an analytical approach for N-linked glycan analysis using the SLIM-based high-resolution ion mobility platform MOBIE. Results will be shown for each aspect of the overall strategy and how this platform can be an integral part for the characterization of protein therapeutics.

To combat the COVID-19 pandemic, comprehensive characterization of humoral and cellular immune responses to SARS-CoV-2 is essential.

New methods, techniques and efficient data analysis software in liquid chromatography-tandem mass spectrometry (LC-MS/MS) hold the key for accelerating the development of NGBs and increasing their availability.

The global market for antibody therapeutics is rising rapidly and newer, engineered modalities such as bi-specific antibodies and antibody fragments are entering clinical studies in record number

Biopharmaceutical companies are transitioning from the development of standard monoclonal antibody therapies to more intricate antibody structures and new genetic medicines. Not only are these molecules more complex, but scientists are also under tremendous pressure to understand molecular liabilities sooner and close the developability gap in a much shorter time frame.

Vanderbilt University Medical Center researchers Robert Carnahan and Pavlo Gilchuk are attempting to compress the timeline for therapeutic antibody development, by integrating a series of advances in single-cell messenger RNA sequence analysis, bioinformatics, synthetic biology and high-throughput functional analysis.

Single domain antibodies (sdAbs) have seen a tremendous uptake in various fields. Attend this webinar to discover the versatility of sdAb technology in antibody drug development and to explore various analytical methods developed using sdAbs.

In this webinar, David Roberts will present novel top-down proteomics and nanotechnology approaches for the sensitive enrichment, analysis, and characterization of low-abundance protein biomarkers.